AromataseinhibitorsVenlafaxineTNBCIntermediate(11-25)2yearsChemoendocrinetherapyPertuzumabLVEFmonitoringOlaparibPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)Taxanes1yearTDM-1(Ado-trastuzumabemtansine)TamoxifenEverymonthExemestaneAbemaciclibRadiationtherapyCapecitabinePembrolizumab10yearsTC (docetaxel /cyclophosphamide)AnthracyclinesLoperamideprophylaxisAromataseinhibitorsVenlafaxineTNBCIntermediate(11-25)2yearsChemoendocrinetherapyPertuzumabLVEFmonitoringOlaparibPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)Taxanes1yearTDM-1(Ado-trastuzumabemtansine)TamoxifenEverymonthExemestaneAbemaciclibRadiationtherapyCapecitabinePembrolizumab10yearsTC (docetaxel /cyclophosphamide)AnthracyclinesLoperamideprophylaxis

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Aromatase inhibitors
  2. Venlafaxine
  3. TNBC
  4. Intermediate (11-25)
  5. 2 years
  6. Chemoendocrine therapy
  7. Pertuzumab
  8. LVEF monitoring
  9. Olaparib
  10. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  11. Taxanes
  12. 1 year
  13. TDM-1 (Ado-trastuzumab emtansine)
  14. Tamoxifen
  15. Every month
  16. Exemestane
  17. Abemaciclib
  18. Radiation therapy
  19. Capecitabine
  20. Pembrolizumab
  21. 10 years
  22. TC (docetaxel / cyclophosphamide)
  23. Anthracyclines
  24. Loperamide prophylaxis